Prostate Tumour Overexpressed-l (PTOVl) was recently identified as a novel gene and protein during a differential display screening for genes overexpressed in PCa. It has been suggested that overexpression of PTOVI can contribute to the proliferative status of prostate tumour cells and thus to their biological behaviour (1) (2) (3) (4) (5) . The protein PTOVI is overexpressed immunohistochemically in over 70% of PCa cases (3, 5) .
u-Methyl-CeA racemase (AMACR) mRNA was identified as being overexpressed in PCa (6) . Immunohistochemical studies with an antibody directed against the protein encoded by this mRNA demonstrate that over 80% of PCa cases are labeled (7) .
In the current study, PTOVI and AMACR were immunohistochemically evaluated in PCa as well as in HGPIN, atrophy and NEp in RPs. The aim was to see whether there were differences between PTOVI and AMACR. To the best of our knowledge there are no previous studies comparing the tissue expression of these two markers.
MATERIALS AND METHODS
Twenty RP specimens with hormonally untreated acinar PCa were obtained from the five Pathology Services associated with the Polytechnic University of the Marche Region-United Hospitals. These cases were from men with clinically detected PCa. HGPIN was present in all 20 . Patient characteristics are shown in Table 1 .
All patients were Caucasian men from the Marche Region, located in Eastern Central Italy, where a relatively homogenous population lives. The procedure for this research project conforms to the provisions of the Declaration of Helsinki.
The whole-mount technique with complete sampling was used to process the surgical specimens. Briefly, each prostate specimen was covered with India ink and fixed for 24 h in 4% neutral buffered formalin. After fixation, the prostate specimens were step-sectioned at 0.3 cm intervals perpendicular to the long axis (apical-basal) of the gland. The apex, base, and seminal vesicles were removed from each specimen and submitted in total for routine histological examination. The cut specimens were post-fixed for an additional 24 h and then dehydrated in graded alcohols, cleared in xylene, embedded in paraffin, and examined histologically as 5 um-thick whole-mount haematoxylin and eosin (H&E) stained sections.
The most representative block(s) containing compartments of NEp, atrophy, HGPIN and PCa were selected. The samples selected for the study were all from the peripheral zone of the prostate to avoid that the results of PTOV I and AMACR expression were influenced by their zonal distribution. The PCa of these two groups was pT2a and Gleason score 6 (3+3), because we planned to study a homogenous population, avoiding the influence of stage and grade.
Tissue representing all three compartments was mapped out on H&E-stained slides using marker pens. Different colors were used to mark out NEp, atrophy, HGPIN and PCa. HGPIN glands that were in close proximity and within I mm distance of the tumors were considered to be adjacent and glands that were at least 5 mm distant were considered to be away from PCa (see below) (8) . Five-micron thick sections were cut from archival, formalin-fixed, paraffin embedded specimens, and mounted on silane-coated slides.
Immunohistochemical staining
To evaluate PTOVI and AMACR, standard indirect biotin-avidin immunohistochemical analysis was performed. Antigen retrieval was carried out with EDTA buffer, 100°C, in a pressure steamer for 90 min. The slides were stained on an automated immunostainer (DakoCytomation, Denmark), using a polyclonal anti-PTOVI antibody (DakoCytomation, Denmark; I: 50 dilution) and a polyclonal anti-AMACR antibody (DakoCytomation, Denmark; 1:2,000 dilution). Bound antibodies were detected with the Dako Envision™ System. As a negative control, primary antibody was omitted and replaced with phosphate-buffered saline. In addition, non-specific rabbit antibody was used and gave clean negative results in all cases tested (not shown). Slides were counter-stained with a light haematoxylin. All staining was performed within 3 days of slide preparation to prevent antigen degradation. Prostate cancer samples previously tested and with known expression ofPTOVI andAMACR were used as positive controls.
The maps made on the H&E-stained slides were traced out on the corresponding immunostained slides (see above). At least 1,000 cells were counted in contiguous 400X microscopic fields in each case separately for NEp, atrophy, HGPIN adjacent to and away from PCa, and PCa. Immunohistochemistry was evaluated as follows: 1. PTOVI. Immunostaining was seen in the cytoplasm of the secretory cells. Few positive nuclei were seen in HGPIN and PCa and never independently from the cytoplasmic staining. For this reason an attempt to report the nuclear staining separately from the cytoplasmic was not made. 2. AMACR. Staining was seen only in the secretory cells. Diffuse evenly dispersed brawn cytoplasmic or concentrated apical granular staining of moderate and 'strong intensity was defined as a positive result for AMACR. Cell membrane between adjacent cells with strong cytoplasmic immunoreactivity was not always recognizable. However, the identification of individual cells was still feasible on the basis of the presence of the nucleus. Examples of PTOVI and AMACR expression in NEp and PCa are depicted in Fig. 1 , A to D. Each slide was assessed independently by two pathologists. Discrepancies were resolved by a concurrent re-examination by both investigators using a doubleheaded microscope. PTOVI and AMACR expression was evaluated in a semiquantitative manner whereby the levels of expression are represented as the percentage of positive cells and the intensity of the staining [Hscore = 1 x (% weak) + 2 x (% moderate) + 3 x (% intense) with a ranking between 0 and 300] (9).
Statistical analysis
Statistics were carried out with SPSS software (SPSS Inc., Chicago, Illinois, USA). It included Mann-Whitney test and ROC (receiver-operator characteristic) curves . The differences between the groups were considered statistically significant at a value of p<O.05.
RESULTS

Normal-looking epith elium and atrophy
The Hscore values for the PTOV I expression in NEp were slightly higher than those seen with AMACR (PTOVI: mean 7.52± standard deviation, SD, 6.37; AMACR: 2.67±11.07). The difference between PTOVI and AMACR was statistically significant (p<O.OOI) (Table II) .
In atrophy the Hscore values for PTOVI were slightly higher than those seen for AMACR (PTOV I: 20.3±9; AMACR: 13.5±29.95), the difference being statistically significant (p<O.OO I).
The differences between NEp and atrophy were statistically significant (Tables III and IV) .
High-grade prostatic intraepithelial neoplasia
The Hscore values for PTOV I were higher than for AMACR. When HGPlN was away from PCa the values were lower than when adjacent to it (PTOVI, away : IOO.57±25.69; adjacent: 132.7±39.14; AMACR, away : 42.59±39.57; adjacent: 130.35±80.86). The differences between PTOV I and AMACR expression were significant only for the away location (p=O.OO I) ( Table II) .
The Hscore values were greater than those seen in Nep and atrophy, the differences between HGPIN and Nep and between HGPIN and atrophy being statistically significant (Tables III and IV) .
The differences between the adjacent and away locations were statistically significant both for the PTOVI (p=0.012) andAMACR (p<0.001).
Prostate cancer
The Hscore values for PTOVI andAMACR were greater than those in the adjacent HGPIN. The values for PTOVI were lower than in the AMACR group (PTOVI: 145.65±37.42; AMACR: 205.5±64.13), difference being statistically significant (p=0.002) (Table II) .
Additional comparisons with statistically significant differences are reported in the confusion matrixes of Tables III and IV .
Statistics
With the ROC curve analysis the overall accuracy (as expressed by the area under each curve) in distinguishing PCa vs HGPIN away from and adjacent to cancer was higher for AMACR than for PTOVI (PCa vs HGPIN away: AMACR, area under the curve 0.981, p<O.OOI; PTOVI 0.843, p<O.OOl. PCa vs HGPIN adjacent: AMACR, 0.778, p=0.003; PTOVI, 0.616, p=O.I77, not significant). Additional ROC analysis results are reported in Table V .
DISCUSSION
Prostate Tumour Overexpressed-I was identified as a novel gene and protein during a differential display screening for genes overexpressed in prostate cancer (I). The protein is encoded by a 12-exon gene localized in chromosome 19q13.3. It consists of two highly homologous domains of 151 and 147 amino acids arranged in tandem, joined by a short linker peptide. The PTOVI domain is conserved across distant organisms and does not show significant similarities to known protein motifs (I).
In quiescent cultured prostate tumour cells, PTOVI is localized to the cytoplasm, being excluded from nuclei. After serum stimulation, PTOVI partially translocates to the nucleus at the beginning of the S phase. At the end of mitosis, PTOVI exits the nucleus. Transient transfection of chimeric green fluorescent protein-PTOVI forces the entry of cells into the S phase ofthe cell cycle, as shown by double fluorescent imaging for green fluorescent protein and for Ki67, and also by flow cytometry. These observations suggest that PTOVI contribute to the proliferative status of cells (1, 4, 5) .
The protein PTOVI is overexpressed in 71% and 80% of pea and HGPIN cases, respectively, while it is expressed at low levels in normal prostate epithelium (3, 5) . PTOVI is expressed at high levels in neuroendocrine cells and in endothelial cells (9) . High levels ofPTOV I in prostatic tumours correlated significantly with Ki67 proliferative index and (4) . Transient overexpression of a chimeric GFP-PTOVI protein induces proliferation and forces the entry of cells into the S phase of the cell cycle, suggesting that overexpression ofPTOV1 can contribute to the biological behaviour of these tumours (5) .
A previous study from our group (9) found that PTOVI expression in cystoprostatectomy (CyP) and RP specimens increased from NEp to HGPlN to PCa. These results, similar to those obtained by Ananthanarayanan et at. (8) in cell proliferation, gave support to the presence of a field effect in prostatic carcinogenesis. Some differences in marker expression between CyPs and RPs were observed. Such an observation suggested that there are differences in the field effects in terms of carcinogenesis between the two types of specimens (9) (10) (11) (12) (13) (14) (15) .
a-Methyl-CoA Racemase mRNA was identified as being overexpressed in PCa by cDNA library subtraction utilizing high throughput RNA microarray analysis (6) . This mRNA was found to encode a racemase protein, for which polyclonal and monoclonal antibodies have been produced which are active in formalin-fixed, paraffin-embedded tissue (16) (17) (18) (19) . Immunohistochemical studies on biopsy material with an antibody directed against AMACR (P504S) demonstrate that over 80% of prostatic adenocarcinomas are labeled (18) . Certain subtypes of prostate cancer, such as foamy gland carcinoma, atrophic carcinoma, pseudohyperplastic, and treated carcinoma show lower AMACR expression.
However, AMACR is not specific for PCa and is present in nodular hyperplasia (12%), atrophic glands (36%), HGPlN (>80%) (20) and atypical adenomatous hyperplasia (adenosis) (17.5%) (20) . AMACR may be used as a confirmatory stain for PCa, in conjunction with H&E morphology and a basal cell specific marker (20) . AMACR is expressed in other non-prostatic neoplasms, including urothelial, kidney and colon cancer.
A previous investigation from our group (15) found that the AMACR expression in PCa in CyPs was slightly lower than in RPs. NEp, atrophy and HGPIN were investigated both near and away from cancer to see whether there were evidence for and differences in field effects in prostatic carcinogenesis. NEp, atrophy and HGPIN near PCa showed a higher level of AMACR expression and a greater level of cell proliferation indices compared to NEp, atrophy and HGPIN away from cancer (15) . In the current study the level of PTOV1 and AMACR expression increased from NEp and atrophy through HGPIN to PCa. With the ROC curve analysis the overall accuracy in distinguishing PCa vs HGPIN away from and adjacent to cancer was higher for racemase than for PTOVI. To the best of our knowledge there are no previous studies comparing the expression ofPTOVl with that ofAMACR. The limitations of our study are represented by the small number of cases investigated and by the fact that the full range of variants of PCa and of Gleason score cancers was not investigated.
It is worth mentioning a recent study (21) in which the usefulness of AMACR inthe diagnosis of PCa was compared with that of fatty acid synthase (FASn). Similar to AMACR, there was significantly higher FASn expression in PCa compared with that in benign glands. The optimal accuracy rate and area under curve by receiver-operating characteristic analysis for FASn were not significantly different from those for AMACR. Moreover, in cases with coexistent malignant and benign glands on the same core, FASn could selectively distinguish a proportion of cases similar to using AMACR. From the practical point of view, the results of such study confirms our current findings thatAMACR is still to be considered the tissue marker of choice in the diagnosis of PCa.
In conclusion, PTOV1 may aid in the diagnosis of PCa, at least to supplement AMACR as another positive marker of carcinoma and potentially increase diagnostic accuracy.
